Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

, Shire will present the highlights of new data from an exploratory study for VYVANSE as adjunctive therapy in adults with significant cognitive impairments with partially or fully remitted MDD. This study met its primary and secondary endpoints.


 

  • A Phase 3 clinical trial program to assess the efficacy and safety of VYVANSE as adjunctive therapy in patients with MDD has been initiated.

BOARD CHANGES

Mr Patrick Langlois, who has been a member of Shire's Board of Directors for 6 years, will be stepping down from the Board and from the Company's Audit, Compliance & Risk Committee and its Remuneration Committee on the expiry of his current term of office on November 10, 2011. Matthew Emmens, Chairman of Shire, said "We thank Patrick for his contribution to Shire over the past few years".

ADDITIONAL INFORMATION

The following additional information is included in this press release:

Page Overview of Third Quarter 2011 Financial Results 6 Financial Information 10 Non GAAP Reconciliations 19 Safe Harbor Statement 23 Explanation of Non GAAP Measures 24 Trademarks 25

OVERVIEW OF THIRD QUARTER 2011 FINANCIAL RESULTS

1.    Product sales

For the three months to September 30, 2011 product sales increased by 28% to $1,018.4 million (Q3 2010: $794.3 million) and represented 94% of total revenues (Q3 2010: 91%).

Product Highlights

US Exit Market Year on year growth Share(1) Sales $M Sales CER US Rx(1) Product VYVANSE 199.7 +32% +32% +20% 16% ADDERALL XR 149.9 +50% +50% +8% 7% REPLAGAL 129.0 +40% +31% n/a(3) n/a(3) ELAPRASE(R) 109.6 +13% +7% n/a(2) n/a(2) LIALDA/MEZAVANT(R) 89.7 +18% +17% +7% 21% VPRIV 64.6 +31% +27% n/a(2) n/a(2) INTUNIV(R) 56.1 +50% +50% +59% 4% PENTASA(R) 55.9 -2% -2% -4% 15% DERMAGRAFT 50.0 n/a n/a n/a(2) n/a(2) FOSRENOL(R) 40.5 -10% -14% -17% 5% FIRAZYR 7.2 +148% +129% n/a(2) n/a(2) RESOL
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , September 18, 2014 ... ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced the ... - Global Strategic Business Report" ... http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes the worldwide ... Million by the following Product Segments: ...
(Date:9/18/2014)... 2014 Research and Markets has ... Stem Cell Industry Report, 2014-2017" report to their ... cells that can differentiate into specialized cells and can ... cell therapy can be applied to treatment of cardiovascular ... system diseases, damage or lesion of liver, kidney and ...
(Date:9/18/2014)... , Sept. 18, 2014 Research ... "Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, ... report to their offering. The global ... CAGR of 22.7% from 2014 to 2019. Factors such ... growing adoption of companion diagnostics by the pharmaceutical industry, ...
(Date:9/18/2014)... Pharma, Inc. (Nasdaq: MEIP ), an oncology company ... announced today that Daniel P. Gold , Ph.D., President ... in the Biotech Industry conference on Friday, September 26, ... Hotel & Conference Center in New York ... at www.meipharma.com . A replay will be available approximately ...
Breaking Biology Technology:Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3
... Product Revenue Increased 78 Percent Compared with 2007 - ... - Net Loss Narrows - - Quantitative ... - Conference Call Today ... (Nasdaq: GHDX ) today reported financial results and business progress,for the quarter ended ...
... APS Healthcare, one of the,country,s leading specialty healthcare companies, ... White Plains. The company now,occupies 44,082 square feet of ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081105/NY44126LOGO ), Ultimately, the move ... Plains.,To date, the company has hired more than 70 ...
... Nov. 5 As biopharmaceutical,companies continue to ... placed on strategy and execution from development ... revenue growth and little else. In,a continuing ... recent study,was conducted by Best Practices, LLC ...
Cached Biology Technology:Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress 2Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress 3Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress 4Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress 5Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress 6Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress 7Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress 8APS Healthcare Moves Headquarters to White Plains, NY 2New Study Provides Key Findings for Biopharma Product Launch Evaluation 2
(Date:9/18/2014)... celebrated tonight at the third annual Golden Goose Award ... premature infants and in paving the way for the ... supported by the National Science Foundation, the National Institutes ... be honored at a ceremony at the Library of ... of Congress will be on hand to help present ...
(Date:9/18/2014)... Sydney, September 18, 2014 Elsevier, a world-leading ... and services, and the Australasian Research Management Society ... young scientists at the 5th Scopus Young Researcher ... held earlier today at the National Convention Centre ... conference, was attended by guests representing Australia,s and ...
(Date:9/18/2014)... is probably the ultimate form of camouflage: you don,t ... this strategy is not as uncommon as you might ... County, USA, explains that the larval life stages of ... part of the anatomy that most creatures cannot make ... have to shield each individual eye unit with an ...
Breaking Biology News(10 mins):3rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2Transparent larvae hide opaque eyes behind reflections 2
... A new research study at the University of Delaware ... microorganism that lives in seawater and is related to ... and virulence. V. parahaemolyticus is a ... with the consumption of raw or undercooked seafood, particularly ...
... dogs in western and central Africa comes from a ... ago, probably by European colonialists. In the current issue ... of scientists from Africa, USA and France report that ... country level and that there is only limited movement ...
... beneficial effect of anakinra for rheumatoid arthritis patients, but ... use with other biologic medications. Rheumatoid arthritis is ... in 100 people worldwide. It affects the joints, making ... new breed of arthritis drugs licensed in the past ...
Cached Biology News:UD research study to shed light on emerging seaborne pathogen 2UD research study to shed light on emerging seaborne pathogen 3Hope for a rabies eradication strategy in Africa 2Anakinra for rheumatoid arthritis: A modest benefit with some risk 2
The product contains 10 ml Dynabeads Epoxy (4.5 m). Supplied at 4 x 10 8 beads/ml...
Immunogen: Synthetic peptide: M(1) C V P R S G L I L S(11) Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
...
Biology Products: